Skip to Main Content

Once again, Gilead Sciences is facing a challenge to a European patent over its Sovaldi hepatitis C treatment, which is a building block for subsequent medicines the drug maker has launched.

The latest challenge was filed by various groups, led by Medecins du Monde and Doctors Without Borders, that claim the patent is not warranted under European laws. Specifically, the groups maintain the base compound is not inventive, which is a way of saying the patent is not sufficiently unique that someone else could not have created it.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.